NEW YORK (GenomeWeb News) – Agilent Technologies reported after the close of the market on Thursday that revenues for the first quarter of its Fiscal Year 2014 were flat year over year while Life Sciences and Diagnostics revenues ticked up 5 percent.

For the three months ended Jan. 31, total revenues of $1.68 billion narrowly missed the consensus Wall Street estimate of $1.69 billion. Orders of $1.68 billion were down 2 percent from $1.71 billion a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.